ArticleNature medicine2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Lin Shen et al.PubMed ↗Publisher ↗
No numbers read from the abstract.